

瑋俊生物科技有限公司 Wai Chun Bio-Technology Limited

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 0660)

2023 / 24
Interim Report

CONTENTS

	Page
Corporate Information	2
Management Discussion and Analysis	3
Other Information	7
Condensed Consolidated Statement of Profit or Loss	15
Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income	16
Condensed Consolidated Statement of Financial Position	17
Condensed Consolidated Statement of Changes in Equity	19
Condensed Consolidated Statement of Cash Flows	20
Notes to the Condensed Consolidated Financial Statements	21

CORPORATE INFORMATION

As at 29 February 2024

BOARD OF DIRECTORS Executive Director

Lam Ka Chun

Independent Non-Executive Directors

Wan Bo Hong Ting Hung Hoi Ming Raymond (resigned on 9 August 2023)

AUTHORISED REPRESENTATIVES

Lam Ka Chun
LI Huifang
(appointed on 15 February 2024)
HE Xiaoping (appointed on 14 July 2023
and resigned on 15 February 2024)
Fenn David (resigned on 14 July 2023)

COMPANY SECRETARY

LI Huifang
(appointed on 15 February 2024)
HE Xiaoping (appointed on 14 July 2023
and resigned on 15 February 2024)
Fenn David (resigned on 14 July 2023)

AUDIT COMMITTEE

Hong Ting (Chairman) Wan Bo Hung Hoi Ming Raymond (resigned on 9 August 2023)

REMUNERATION COMMITTEE

Hong Ting (Chairman)
Lam Ka Chun
Wan Bo
Hung Hoi Ming Raymond
(resigned on 9 August 2023)

NOMINATION COMMITTEE

Wan Bo (Chairman)
Lam Ka Chun
Hong Ting
Hung Hoi Ming Raymond
(resigned on 9 August 2023)

REGISTERED OFFICE

P.O. Box 31119
Grand Pavilion
Hisbiscus Bay
802 West Bay Road
Grand Cayman KY1-1205
Cayman Islands

HEAD OFFICE AND PRINCIPAL PLACE OF BUSINESS IN HONG KONG

Room 4001-02, 40/F. China Resources Building 26 Harbour Road, Wanchai Hong Kong

AUDITOR

CCTH CPA Limited

Certified Public Accountants
15/F., Tower 2

Kowloon Commerce Centre
15 Kwai Cheong Road

Kwai Chung

New Territories, Hong Kong

SHARE REGISTRAR IN HONG KONG

Union Registrars Limited Room 3301–04, 33/F. Two Chinachem Exchange Square 338 King's Road North Point Hong Kong

PRINCIPAL BANKER

Hang Seng Bank Limited Bank of China (Hong Kong) Limited

STOCK CODE

0660

COMPANY WEBSITE

http://www.0660.hk

FINANCIAL REVIEW Financial Performance

For the six months ended 31 December 2023, the Group recorded a revenue of approximately HK\$190,330,000 (for the six months ended 31 December 2022: approximately HK\$405,080,000), representing a decrease of 53.0% as compared with that of for the six months ended 31 December 2022. The decrease in revenue was due to the decrease in market consumption and demand during the period. The Group recorded a gross profit and gross profit margin of approximately HK\$16,795,000 and 8.8% respectively for the six months ended 31 December 2023, representing a decrease of approximately HK\$9,896,000 and a decrease of 37.1% respectively as compared with the gross profit of approximately HK\$26,691,000 and gross profit margin of 6.6% for the six months ended 31 December 2022.

Administrative expenses decreased by 10.9% from approximately HK\$10,566,000 for the six months ended 31 December 2022 to approximately HK\$9,412,000 for the six months ended 31 December 2023. The decrease in administrative expenses was mainly because of the tighter cost control measures of the Group and the decrease in staff costs in Hong Kong. Selling expenses recorded a decrease of 6.6% from approximately HK\$7,428,000 for the six months ended 31 December 2022 to approximately HK\$6,938,000 for the six months ended 31 December 2023.

Loss attributable to owners of the Company amounting to approximately HK\$6,734,000 for the six months ended 31 December 2023 as compared with the loss attributable to owners of the Company amounting to approximately HK\$7,831,000 for the six months ended 31 December 2022. The decrease in loss attributable to owners of the Company was mainly due to recognition of reversal of impairment losses on trade receivables during the period under review.

Financial Resources and Position

As at 31 December 2023, the Group had net current liabilities of approximately HK\$45,586,000 (30 June 2023: approximately HK\$29,657,000) and cash and cash equivalents of approximately HK\$5,435,000 (30 June 2023: approximately HK\$6,312,000).

As at 31 December 2023, the current ratio of the Group was approximately 0.79 times (30 June 2023: approximately 0.81 times). The net debts (net of cash and cash equivalents) to total assets ratio of the Group was approximately 43.8% (30 June 2023: approximately 53.3%).

During the six months ended 31 December 2023, the Group financed its operations mainly by internally generated resources, loan from the ultimate holdings company and borrowings. The Group's cash and cash equivalents are mainly denominated in Hong Kong Dollars, Renminbi and United States Dollars. The Group conducted its business transactions principally in Renminbi and United States Dollars. The Group has not experienced any material difficulties or negative impact on its operations as a result of fluctuations in currency exchanges rates.

CONVERTIBLE BONDS, BORROWINGS AND LOANS FROM THE ULTIMATE HOLDING COMPANY

An analysis of the maturity of convertible bonds is set out below.

	31 December 2023 HK\$'000 (Unaudited)	30 June 2023 HK\$'000 (Audited)
Within one year Over one year but less than two years Over two years but less than five years	- - 72,888	- - 69,729
	72,888	69,729

As at 31 December 2023 and 30 June 2023, the convertible bonds were non-interest bearing and denominated in Hong Kong dollars. As at 31 December 2023 and 30 June 2023, the effective interest rates of the convertible bonds were in the range from 15.91% to 25.37% per annum.

As at 31 December 2023, included in the carrying amount of borrowings, approximately HK\$58,181,000 (30 June 2023: HK\$59,289,000) was secured bank loans. Such secured bank loans are secured by the pledge of the Group's certain right-of-use assets, denominated in Renminbi, bearing interest at floating interest rate and repayable within one year.

As at 31 December 2023, included in the carrying amount of borrowings, approximately HK\$2,570,000 (30 June 2023: HK\$2,570,000) was loans from independent third parties. The amount was unsecured, denominated in Hong Kong dollars, bearing interest at an interest rate of 6.25% per annum and repayable on demand.

As at 31 December 2023, approximately HK\$4,641,000 (30 June 2023: HK\$2,513,000) was loans from the ultimate holding company. The amount is unsecured, denominated in Hong Kong dollars, bearing interest at an interest rate of 6.25% per annum and repayable on demand.

BUSINESS REVIEW AND OUTLOOK

During the period under review, the Group continued to engage in the manufacturing and sale of modified starch and other biochemical products.

During the period under review, the business of manufacturing and sales of modified starch and biochemical products recorded segment profit of approximately HK\$7,959,000 (for the six months ended 31 December 2022: segment profit of approximately HK\$8,067,000).

The Group will continue to pursue strategic acquisitions that can enable the Company to capture new business opportunities in the PRC market and to strengthen the revenue and profit fundamentals. The Company has been actively identifying projects with growth potential for acquisitions or investments and has been in discussions with various parties for such acquisitions or investments.

In order to ensure the Group's financial ability to operate as a going concern, the directors of the Company (the "Directors") have been implementing various measures including the provision of loan facilities by the ultimate holding company, conducting negotiation with potential investors to raise sufficient funds; and will continue to implement measures aiming at improving the working capital and cash flows of the Group including closely monitoring general administrative expenses and operating costs.

PLEDGE OF ASSETS

Certain of the Group's right-of-use assets were pledged to secure certain bank borrowings granted to the Group.

CONTINGENT LIABILITIES

The Group did not have any material contingent liabilities as at 31 December 2023 (as at 30 June 2023: Nil).

SIGNIFICANT INVESTMENTS

As at 31 December 2023, the Group did not have any significant investments.

MATERIAL ACQUISITIONS AND DISPOSALS OF SUBSIDIARIES, ASSOCIATES AND JOINT VENTURES

There was no material acquisition or disposal of subsidiaries, associates and joint ventures, which would have been required to be disclosed under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules"), for the six months ended 31 December 2023.

FUTURE PLANS FOR MATERIAL INVESTMENTS OR CAPITAL ASSETS

Save for the capital expenditure on property, plant and equipment as may be required by the Group's business operations, as at 31 December 2023, the Group did not have any plans for material investments and capital assets. Such capital expenditure will generally be funded by internal generated cash flows and borrowings.

INTERIM DIVIDEND

The board of directors (the "Board") resolved not to recommend the payment of any interim dividend for the six months ended 31 December 2023 (for the six months ended 31 December 2022: Nil).

DIRECTORS' AND CHIEF EXECUTIVE'S INTERESTS AND SHORT POSITIONS IN SHARES, UNDERLYING SHARES AND DEBENTURES

As at 31 December 2023, none of the Directors or chief executive of the Company had any interests or short positions in the shares, underlying shares and debentures of the Company or any of its associated corporation(s) (within the meaning of Part XV of the Securities and Future Ordinance (the "SFO")) as recorded in the register of interests required to be kept by the Company under Section 352 of the SFO, or as otherwise notified to the Company and The Stock Exchange of Hong Kong Limited (the "Stock Exchange") pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests or short positions) which they are taken or deemed to have taken under such provisions of the SFO and pursuant to the Model Code for Securities Transactions by Directors of Listed Issuers (the "Model Code") set out in Appendix C3 of the Listing Rules.

SUBSTANTIAL SHAREHOLDERS

Save as disclosed below, as at 31 December 2023, so far as was known to the Directors or chief executive of the Company, the Company had not been notified by any persons (other than the Directors or the chief executive of the Company) who had interests or short positions in the shares or underlying shares of the Company which would fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO or which were recorded in the register required to be kept by the Company under Section 336 of the SFO

Long positions in the shares of the Company (the "Shares")

Name of shareholder	Capacity/nature of interest	Number of Shares/underlying Shares held	percentage of the number issued Shares
Mr. Lam Ching Kui (Note 1)	Beneficial owner	268,072,400	156.33%
	Interest of controlled corporation	221,150,243	128.97%
Wai Chun Investment Fund (Note 1)	Interest of controlled corporation	221,150,243	128.97%
Chinese Success Limited ("Chinese Success") (Note 1)	Beneficial owner	221,150,243	128.97%
Onward Global Investments Limited ("Onward Global") (Note 2)	Beneficial owner	12,863,500	7.50%
Wan Yuzhen (Note 2)	Beneficial owner Interest of controlled corporation	100 12,863,500	0.00% 7.50%

Annrovimato

Name of shareholder	Capacity/nature of interest	Number of Shares/underlying Shares held	Approximate percentage of the number issued Shares
Fair Concourse Limited ("Fair Concourse") (Note 3)	Beneficial owner	14,127,040	8.24%
Chen Guanyu (Note 3)	Interest of controlled corporation	14,127,040	8.24%
South Bright Holdings Limited ("South Bright") (Note 4)	Beneficial owner	10,172,337	5.93%
Wan Qian Yi (Note 4)	Interest of controlled corporation	10,172,337	5.93%

Notes:

(1) Chinese Success, which is wholly owned by Wai Chun Investment Fund, holds 84,550,243 shares of the Company. Mr. Lam Ching Kui, directly holds 72,400 shares and is the beneficial owner of the entire issued share capital of Wai Chun Investment Fund. As at 31 December 2023, Mr. Lam Ching Kui is also the holder of zero coupon convertible bonds in the principal amount of HK\$67,000,000 under which 268,000,000 shares would be issued by the Company upon full exercise of the conversion rights under the aforementioned zero coupon convertible bonds. Mr. Lam Ching Kui is the director of Chinese Success and Wai Chun Investment Fund.

On 22 December 2022, Chinese Success entered into a subscription agreement with the Company for the subscription of convertible bonds to be issued by the Company in the principal amount of HK\$14,000,000 under a specific mandate to be obtained from independent shareholders of the Company at a general meeting. The specific mandate for the issue of the convertible bonds was granted to the Company in an extraordinary general meeting held on 10 March 2023. The completion for the subscription of the convertible bonds took place on 14 March 2023 following the satisfaction of all the conditions, including but not limited to the granting of listing approval by the Stock Exchange. The Company has completed to issue the zero coupon convertible bonds in the principal amount of HK\$14,000,000 to Chinese Success on 14 March 2023, under which 56,000,000 shares would be issued by the Company upon full exercise of the conversion rights under the aforementioned zero coupon convertible bonds.

On 31 March 2023, Chinese Success converted HK\$850,000 zero coupon convertible bonds into 3,400,000 ordinary shares of the Company. Chinese Success is also the holder of zero coupon convertible bonds in the remaining principal amount of HK\$20,150,000 under which 80,600,000 shares would be issued by the Company upon full exercise of the conversion rights under the aforementioned zero coupon convertible bonds.

- (2) As at 31 December 2023, 12,863,500 Shares were held by Onward Global which is wholly owned by Wan Yuzhen. For the purpose of the SFO, Wan Yuzhen is deemed to be interested in these 12,863,500 Shares held by Onward Global. Wan Yuzhen also directly holds 100 Shares.
- (3) As at 31 December 2023, 14,127,040 Shares were held by Fair Concourse which is wholly owned by Chen Guanyu. For the purpose of the SFO, Chen Guanyu is deemed to be interested in these 14,127,040 Shares held by Fair Concourse.
- (4) As at 31 December 2023, 10,172,337 Shares were held by South Bright which is wholly owned by Wan Qian Yi. For the purpose of the SFO, Wan Qian Yi is deemed to be interested in these 10,172,337 Shares held by South Bright.

SHARE OPTION SCHEME

Pursuant to a share option scheme adopted by the shareholders of the Company on 22 July 2015 (the "Share Option Scheme"), the Company may, at their discretion, invite executive or non-executive director, employee (whether full-time or part-time), chief executive, substantial shareholder, consultant, professional and other adviser to take up options.

The subscription price of the Share Option Scheme will be determined at the highest of (i) the closing price of the shares as stated in the Stock Exchange's daily quotations sheet on the date on which an option is granted; (ii) the average closing prices of the shares as stated in the Stock Exchange's daily quotations sheets for the 5 business days immediately preceding the date on which an option is granted; and (iii) the nominal value of a share.

The total number of shares which may be issued upon exercise of all options to be granted under the Share Option Scheme and any other share option schemes of the Group shall not in aggregate exceed 10% of the total number of shares in issue as at the adoption date. Besides, the maximum number of shares which may be issued upon exercise of all outstanding options granted and yet to be exercised under the Share Option Scheme and any other share option schemes of the Group in issue shall not exceed 30% of the relevant class of the shares in issue from time to time. The total number of shares issued and to be issued upon exercise of the options granted to each participant in any 12-month period shall not exceed 1% of the total number of shares in issue.

Options granted under the Share Option Scheme must be taken up within 30 days of the grant upon payment of HK\$1.00 per grant.

Movements of the Company's share options held by consultants and an employee during the six months ended 31 December 2023 are set out below:

Category of participants	As at 1 July 2023	Granted	Exercised	Expired	As at 31 December 2023	Date of grant	Exercise period	Exercise price
Consultants Employee	73,312,222 16,270,685	-	-	(73,312,222) (16,270,685)		16 July 2018 16 July 2018	16 July 2018 to 15 July 2023 16 July 2018 to 15 July 2023	0.720 0.720
Exercisable at end of year/ period	89,582,907	-	-	(89,582,907)	-			

Share options granted on 16 July 2018 expired on 15 July 2023.

EMPLOYEES

As at 31 December 2023, the Group had a total of 130 (30 June 2023: 128) employees. The majority of the Group's employees are situated in the PRC. The staff costs (including directors' emoluments) for the six months ended 31 December 2023 was approximately HK\$3,591,000 (for the six months ended 31 December 2022: HK\$8,920,000). In addition to offering competitive remuneration packages to employees, discretionary bonuses and share options may also be granted to eligible employees based on individual performance.

The Group also encourages its employees to pursue a balanced lifestyle and provides a good working environment for its employees to maximise their potential and contribution to the Group.

DIRECTORS' RIGHTS TO ACQUIRE SHARES OR DEBENTURES

At no time during the six months ended 31 December 2023 was the Company, or any of its subsidiaries, a party to any arrangements to enable the Directors to acquire benefits by means of shares in, or debt securities, including debentures, of the Company or any other body corporate.

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

Neither the Company nor any of its subsidiaries had purchased, sold or redeemed any of the Company's listed securities during the six months ended 31 December 2023.

MODEL CODE FOR SECURITIES TRANSACTIONS BY DIRECTORS

The Company has adopted the Model Code set out in Appendix C3 to the Listing Rules as the code of conduct regarding securities transactions by the Directors. All Directors have confirmed, following specific enquiries by the Company, that they have complied with the required standards as set out in the Model Code during the six months ended 31 December 2023.

CORPORATE GOVERNANCE

The Company has adopted the code provisions of the Corporate Governance Code ("CG Code") as set out in Appendix C1 to the Listing Rules as its own code of corporate governance. During the six months ended 31 December 2023, the Company has complied with the relevant code provisions set out in the CG Code except for the deviation from code provision C.2.1, which is explained below.

Code provision C.2.1 provides that the roles of the Chairman and Chief Executive Officer should be separated and should not be performed by the same individual. The Company did not separate the roles of the Chairman and Chief Executive Officer during the period under review. Mr. Lam Ka Chun is the Chairman and Chief Executive Officer of the Company with effect from 1 November 2023. Mr. Lam Ka Chun has extensive experience in project investment and management and is responsible for the overall corporate strategies, planning and business development of the Group. The balance of power and authorities are ensured by the operation of the Board which comprises experienced and high caliber individuals with sufficient number thereof being Independent Non-Executive Directors.

Mr. Hung Hoi Ming Raymond ("Mr. Hung") resigned as an independent non-executive Director with effect from 9 August 2023 (the "Resignation of Mr. Hung"). Upon the Resignation of Mr. Hung, the Company no longer complied with Rules 3.10(1) and 3.21 of the Listing Rules. The Company is in the process of identifying suitable candidate to fill the vacancy and will use its best endeavours to ensure that suitable candidate is appointed as soon as practicable.

DISCLOSURE UNDER RULE 13.51B(1) OF THE LISTING RULES

Pursuant to Rule 13.51B(1) of the Listing Rules, the changes in information of the directors of the Company are set out below:

Name of Director	Date of change	Details of change
Mr. Hung Hoi Ming Raymond	9 August 2023	Ceased to serve as an independent non-executive Director, a member of each of the audit committee, nomination committee and remuneration committee of the Company
Mr. Lam Ka Chun	1 November 2023	Appointed as chairman of the Board and chief executive officer of the Company

AUDIT COMMITTEE

The Company established an audit committee (the "Audit Committee") in accordance with the requirements of the Listing Rules for the purpose of reviewing and providing supervision over the Group's financial reporting process and internal controls. The terms of reference of the Audit Committee is currently made available on the Stock Exchange's website and the Company's website.

The Audit Committee is mainly responsible for making recommendations to the Board on the appointment, re-appointment and removal of the external auditor and to approve the remuneration and terms of engagement of the external auditor, and any questions of resignation or dismissal of such auditor; reviewing the interim and annual reports and accounts of the Group; and overseeing the Company's financial reporting system (including the adequacy of resources, qualifications and experience of staff in charge of the Company's financial reporting function and their training arrangement and budget) and the internal control procedures.

The Audit Committee currently comprises two independent non-executive Directors, namely Ms. Hong Ting and Mr. Wan Bo. The Audit Committee has reviewed the unaudited interim financial results of the Group and interim report of the Company for the six months ended 31 December 2023.

On behalf of the Board

Wai Chun Bio-Technology Limited

Lam Ka Chun

Chairman and Chief Executive Officer

Hong Kong, 29 February 2024

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS

For the six months ended 31 December 2023

		Six months ended 31 December			
	Notes	2023 HK\$'000 (Unaudited)	2022 HK\$'000 (Unaudited)		
Revenue Cost of sales	4 -	190,330 (173,535)	405,080 (378,389)		
Gross profit Other revenue and other gains and		16,795	26,691		
losses, net Selling expenses Administrative expenses Reversal of impairment losses/ (Impairment losses) on trade and other receivables, net		126 (6,938) (9,412) 5,413	79 (7,428) (10,566) (4,131)		
Finance costs	-	(8,829)	(8,424)		
Loss before tax Income tax expense	5 _	(2,845) (1,185)	(3,779) (1,529)		
Loss for the period	6	(4,030)	(5,308)		
(Loss) profit for the period attributable to:					
Owners of the CompanyNon-controlling interests	-	(6,734) 2,704	(7,831) 2,523		
		(4,030)	(5,308)		
Loss per share	8	HK cents	HK cents (restated)		
- Basic and diluted		(3.93)	(4.57)		

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the six months ended 31 December 2023

	Six months ended 31 December		
	2023 HK\$'000 (Unaudited)	2022 HK\$'000 (Unaudited)	
Loss for the period	(4,030)	(5,308)	
Other comprehensive income (loss): Item that may be reclassified to profit or loss: Exchange differences on translating foreign operations	5,530	(2,902)	
Other comprehensive income (loss), net of tax	5,530	(2,902)	
Total comprehensive income (loss) for the period	1,500	(8,210)	
Total comprehensive income (loss) for the			
period attributable to: - Owners of the Company - Non-controlling interests	(3,914) 5,414	(9,311) 1,101	
	1,500	(8,210)	

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at 31 December 2023

	Notes	31 December 2023 HK\$'000 (Unaudited)	30 June 2023 HK\$'000 (Audited)
Non-current assets Property, plant and equipment Right-of-use assets		103,549 28,098	82,289 28,770
Current assets Inventories Trade receivables Deposits, prepayments and other receivables Tax refundable Bank balances and cash	9	28,606 43,472 56,389 - 5,435	37,577 37,135 47,788 360 6,312
Current liabilities Trade payables Accruals and other payables Contract liabilities Borrowings Tax payable Lease liabilities Loans from the ultimate holding company	10	79,474 28,708 7,027 58,181 754 703 4,641	63,945 24,715 6,697 59,289 - 1,670 2,513
Net current liabilities Total assets less current liabilities		(45,586) 86,061	158,829 (29,657) 81,402

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at 31 December 2023

	31 December 2023 HK\$'000 (Unaudited)	30 June 2023 HK\$'000 (Audited)
Non-current liabilities		
Lease liabilities	1,134	1,134
Convertible bonds	72,888	69,729
	74,022	70,863
Net assets	12,039	10,539
Capital and reserves		
Share capital	42,869	42,869
Reserves	(81,788)	(77,874)
Capital deficiency attributable to owners		
of the Company	(38,919)	(35,005)
Non-controlling interests	50,958	45,544
Total equity	12,039	10,539

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the six months ended 31 December 2023

	Attributable to owners of the Company								_		
	Share capital HK\$'000	Share premium HK\$'000	Other reserve (Note) HK\$'000	Convertible bonds reserve HK\$'000	Share option reserve HK\$'000	Translation reserve HK\$'000	Statutory reserve HK\$'000	Accumulated losses HK\$'000	Sub- total HK\$'000	Non- controlling interests HK\$'000	Total equity HK\$'000
At 1 July 2023 (audited)	42,869	209,982	6,906	10,366	39,864	(2,090)	10,085	(352,987)	(35,005)	45,544	10,539
(Loss) profit for the period Other comprehensive expense for the period: Exchange differences on	-	-	-	-	-	-	-	(6,734)	(6,734)	2,704	(4,030)
translating of foreign operations	_	-	_	-	_	2,820	-	-	2,820	2,710	5,530
Total comprehensive (loss) income for the period Lapse of share option	- -	-	-	-	(39,864)	2,820	-	(6,734) 39,864	(3,914)	5,414 -	1,500
At 31 December 2023 (unaudited)	42,869	209,982	6,906	10,366	-	730	10,085	(319,857)	(38,919)	50,958	12,039
At 1 July 2022 (audited)	42,019	209,982	6,906	31,309	39,864	1,645	8,989	(378,439)	(37,725)	43,762	6,037
(Loss) profit for the period Other comprehensive expense for the period:	-	-	-	-	-	-	-	(7,831)	(7,831)	2,523	(5,308)
Exchange differences on translating of foreign operations		-	-	-	-	(1,480)	-	-	(1,480)	(1,422)	(2,902)
Total comprehensive (loss) income for the period Profit appropriation to	-	-	-	-	-	(1,480)	-	(7,831)	(9,311)	1,101	(8,210)
statutory reserve		_	_	-		-	515	(515)	-	-	
At 31 December 2022 (unaudited)	42,019	209,982	6,906	31,309	39,864	165	9,504	(386,785)	(47,036)	44,863	(2,173)

Note: Other reserve represents the share of a subsidiary's share premium arising from the allotment and issue of shares and deemed contribution from owners of the Company.

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

For the six months ended 31 December 2023

	Six months ended 31 December		
	2023 HK\$'000 (Unaudited)	2022 HK\$'000 (Unaudited)	
Net cash generated from operating activities	24,665	11,866	
Cash flows from investing activities			
Purchase of property, plant and equipment	(24,245)	(2,159)	
Interest received	3	2	
Net cash used in investing activities	(24,242)	(2,157)	
Net cash (used in) generated from financing activities	(1,413)	677	
Net (decrease) increase in cash and			
cash equivalents	(990)	10,386	
Effects of foreign exchange rate changes	113	(159)	
Cash and cash equivalents at	6.210	7.500	
beginning of the period	6,312	7,520	
Cash and cash equivalents at end of the period,			
represented by bank balances and cash	5,435	17,747	

For the six months ended 31 December 2023

1. GENERAL INFORMATION

The Company was incorporated in the Cayman Islands with limited liability. The address of its registered office is P.O. Box 31119, Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman, KY1–1205, Cayman Islands. The address of its principal place of business is Rooms 4001-02, 40th Floor, China Resources Building, 26 Harbour Road, Wanchai, Hong Kong. The Company's shares are listed on the Main Board of the Stock Exchange.

The principal activities of the Group are manufacturing and sale of modified starch and other biochemical products.

In the opinion of the Directors, as at 31 December 2023, Chinese Success Limited, a company incorporated in the British Virgin Islands, is the immediate holding company; Wai Chun Investment Fund ("Wai Chun IF"), a company incorporated in the Cayman Islands, is the ultimate holding company and Mr. Lam Ching Kui ("Mr. Lam") is the ultimate controlling party of the Company, who resigned as the Chairman of the Board, the Chief Executive Officer and an Executive Director of the Company on 18 July 2022. Mr. Lam is the father of Mr. Lam Ka Chun, an Executive Director, Chairman of the Board and Chief Executive Officer of the Company.

The condensed consolidated financial statements are presented in Hong Kong dollars ("HK\$"), which is also the functional currency of the Company. In addition, the functional currencies of certain group entities that operate outside Hong Kong are determined based on the currency of the primary economic environment in which the Group entities operate.

For the six months ended 31 December 2023

2. BASIS OF PREPARATION

The condensed consolidated financial statements have been prepared in accordance with Hong Kong Accounting Standard 34 "Interim Financial Reporting" issued by the Hong Kong Institute of Certified Public Accountants (the "HKICPA") and the applicable disclosures required by the Listing Rules.

The condensed consolidated financial statements should be read in conjunction with the Group's annual financial statements for the year ended 30 June 2023. The accounting policies and methods of computation used in the preparation of the condensed consolidated financial statements are consistent with those used in the Group's annual financial statements for the year ended 30 June 2023.

The Group incurred a loss attributable to owners of the Company of approximately HK\$6,734,000 for the six months ended 31 December 2023 and as at 31 December 2023, the Group had net current liabilities of approximately HK\$45,586,000. These conditions indicate the existence of a material uncertainty which may cast significant doubt on the Group's ability to continue as a going concern. Therefore, the Group may be unable to realise its assets and discharge its liabilities in the normal course of business. The Directors have prepared the condensed consolidated financial statements based on going concern on the assumptions and measures that:

- (a) As at 31 December 2023, the Company has drawn down loan of approximately HK\$4,641,000 and undrawn loan facilities of approximately HK\$65,359,000 granted by Wai Chun IF, its ultimate holding company;
- (b) In addition to the loan facilities granted by Wai Chun IF as stated above, Mr. Lam has also undertaken to provide adequate funds to enable the Group to meet its liabilities and to settle financial obligations to third parties as and when they fall due so that the Group can continue as a going concern and carry on its business without a significant curtailment of operations for the twelve months from the date of approving the condensed consolidated financial statements.

For the six months ended 31 December 2023

2. **BASIS OF PREPARATION** (Continued)

- The Company has planned and is in negotiation with potential investors to raise sufficient funds through fund-raising arrangement; and
- The Directors will continue to implement measures aiming at improving the working capital and cash flows of the Group including closely monitoring general administrative expenses and operating costs.

The Directors have carried out a detailed review of the cash flow forecast of the Group for the twelve-month period from the date of this report after taking into account the impact of above measures, the Directors believe that the Group will have sufficient cash resources to satisfy its future working capital and other financing requirements as and when they fall due in the next twelve months from the date of this report, and accordingly, are satisfied that it is appropriate to prepare the condensed consolidated financial statements on a going concern basis.

Should the Group be unable to continue in business as a going concern, adjustments would have to be made to write down the value of assets to their recoverable amount, to provide for future liabilities which might arise and to reclassify noncurrent assets and liabilities to current assets and liabilities respectively. The effects of these potential adjustments have not been reflected in the condensed consolidated financial statements.

As set out in the paragraphs above, the Group intends to pursue strategic acquisitions that can enable the Company to capture new business opportunities in the People's Republic of China (the "PRC") market and to strengthen the revenue and profit fundamentals. The Company has been actively identifying projects with growth potential for acquisitions or investments and has engaged in discussions with various parties for such acquisitions or investments.

For the six months ended 31 December 2023

3. APPLICATION OF NEW AND REVISED HONG KONG FINANCIAL REPORTING STANDARDS

In the current period, the Group has adopted all the new and revised Hong Kong Financial Reporting Standards ("HKFRSs") issued by the HKICPA that are relevant to its operations and effective for its accounting year beginning on 1 July 2023. HKFRSs comprise Hong Kong Financial Reporting Standards, Hong Kong Accounting Standards, and Interpretations. The adoption of these new and revised HKFRSs did not result in significant changes to the Group's accounting policies, presentation of the Group's condensed consolidated financial statements and amounts reported for the current period and prior period.

The Group has not applied the new and revised HKFRSs that have been issued but are not yet effective. The Group does not expect that the application of these new and revised HKFRSs would have material impact on its results of operations and financial position.

4. REVENUE AND SEGMENT INFORMATION

Revenue from manufacturing and sale of modified starch and other biochemical products for the six months ended 31 December 2023 were approximately HK\$190,330,000 (for the six months ended 31 December 2022: approximately HK\$405,080,000).

Disaggregation of revenue from contracts with customers

For the six months ended 31 December 2023, the revenue from manufacturing and sale of modified starch and other biochemical products are derived from customers in the PRC in the amounts of approximately HK\$190,330,000 (for the six months ended 31 December 2022: approximately HK\$387,331,000 and HK\$17,749,000 derived from customers in the PRC and Russia respectively).

The Group recognised revenue when the products are transferred to the customers at a point in time.

The Group has one reportable segment as follows:

Modified starch and other biochemical products

 Manufacturing and sale of modified starch and other biochemical products

Segment profits or losses do not include other income and other gains and losses, net, central administration costs, finance costs and income tax expenses.

The Group accounts for intersegment sales and transfers as if the sales or transfers were to third parties, i.e. at current market prices.

For the six months ended 31 December 2023

4. REVENUE AND SEGMENT INFORMATION (Continued) Segment revenue and results

The following is an analysis of the Group's revenue and results by reportable and operating segment:

For the six months ended 31 December 2023

	Modified starch and other biochemical products	Total HK\$'000
	HK\$'000 (Unaudited)	(Unaudited)
Revenue from external customers	190,330	190,330
Segment profit	7,959	7,959
Other revenue and other gains and		
losses, net		126
Central administration costs		(2,101)
Finance costs	-	(8,829)
Loss before tax		(2,845)
Income tax expense	-	(1,185)
Consolidated loss for the period	_	(4,030)

For the six months ended 31 December 2023

4. REVENUE AND SEGMENT INFORMATION (Continued)

Segment revenue and results (Continued)

For the six months ended 31 December 2022

	Modified starch and other biochemical products HK\$'000 (Unaudited)	Total HK\$'000 (Unaudited)
Revenue from external customers	405,080	405,080
Segment profit	8,067	8,067
Other revenue and other gains and losses, net Central administration costs Finance costs	-	79 (3,501) (8,424)
Loss before tax Income tax expense	_	(3,779) (1,529)
Consolidated loss for the period	_	(5,308)

For the six months ended 31 December 2023

5. INCOME TAX EXPENSE

31 December 2023 2022 HK\$'000 HK\$'000 (Unaudited) (Unaudited)

Six months ended

Income tax expense comprises:
Current income tax – PRC Enterprise
Income Tax
Provision for the period

1,185 1,529

On 21 March 2018, the Hong Kong Legislative Council passed The Inland Revenue (Amendment) (No. 7) Bill 2017 (the "Bill") which introduces the two-tiered profits tax rates regime. The Bill was signed into law on 28 March 2018 and was gazetted on the following day. Under the two-tiered profits tax rates regime, the first HK\$2 million of profits of the qualifying group entity will be taxed at 8.25%, and profits above HK\$2 million will be taxed at 16.5%. The profits of group entities not qualifying for the two-tiered profits tax rates regime will continue to be taxed at a flat rate of 16.5%. The Directors considered the amount involved upon implementation of the two-tiered profits tax rates regime is insignificant to the condensed consolidated financial statements. Hong Kong Profits Tax is calculated at 16.5% of the estimated assessable profit for both periods.

No provision for Hong Kong Profits Tax is required since the Group has no assessable profit derived from Hong Kong for both periods.

PRC subsidiaries are subject to PRC Enterprise Income Tax ("EIT") at 25% for both periods, except for the following subsidiary of the Company.

A Company's subsidiary was exempted from PRC income taxes for both periods. According to the Implementation Regulation of the EIT Law and the EIT exemptions regulation set out in the Circular of the Ministry of Finance and the State Administration on Releasing the Primary Processing Ranges of Agricultural Products Entitled to Preferential Policies on Enterprise Income Tax (Trial Implementation) (Cai Shui [2008] No. 149), and the requirements of Article 86 of the Implementation Regulation of the EIT Law, the income from primary processing for agriculture products are exempted from EIT.

For the six months ended 31 December 2023

6. LOSS FOR THE PERIOD

	Six months ended 31 December	
	2023 HK\$'000 (Unaudited)	2022 HK\$'000 (Unaudited)
Loss for the period has been arrived at	,	
after charging (crediting):		
Cost of inventories sold	173,535	378,389
(Reversal of impairment losses) Impairment		
loss on trade and other receivables, net	(5,413)	4,131
Depreciation on property, plant and		
equipment	3,691	3,352
Depreciation on right-of-use assets	1,959	1,915
Staff costs (including directors' emoluments		
and retirement benefit costs)	3,591	8,920

7. INTERIM DIVIDEND

The Board has resolved not to recommend the payment of any interim dividend for the six months ended 31 December 2023 (for the six months ended 31 December 2022: Nil).

8. LOSS PER SHARE

Loss per share

The calculation of basic loss per share attributable to owners of the Company for the six months ended 31 December 2023 is based on the loss attributable to owners of the Company of approximately HK\$6,734,000 (for the six months ended 31 December 2022: loss attributable to owners of the Company of approximately HK\$7,831,000) and the weighted average number of ordinary shares of 171,476,453 (for the six months ended 31 December 2022: adjusted 171,476,453) in issue during the period as adjusted to reflect the effect of the share consolidation. Comparative figures have also been adjusted on the assumption that above consolidation had been effective in prior period.

Diluted loss per share

As the exercise of the Group's outstanding convertible bonds for the six months ended 31 December 2023 and for the six months ended 31 December 2022 would be anti-dilutive and there were no dilutive potential ordinary shares for the Company's outstanding share options and convertible preference shares in both periods, accordingly, the diluted loss per share is same as the basic loss per share in both periods.

For the six months ended 31 December 2023

9. TRADE RECEIVABLES

	31 December 2023 HK\$'000 (Unaudited)	30 June 2023 HK\$'000 (Audited)
Trade receivables Less: Provision for loss allowance	45,882 (2,410)	44,958 (7,823)
Carrying amount	43,472	37,135

The Group allows average credit period of 30 to 180 days to its customers. Receivables that were current relate to customers for whom there was no recent history of default. Provision for impairment is made unless the Group has concluded that recovery is remote, in which case the unrecovered loss is written off against trade receivables and the provision for impairment directly. The Group does not hold any collateral over these balances.

The aging analysis of trade receivables based on the invoice date, and net of allowance, is as follows:

31 December	30 June
2023	2023
HK\$'000	HK\$'000
(Unaudited)	(Audited)
11,571	22,722
12,761	10,722
11,942	1,354
5,368	460
1,830	1,877
43,472	37,135
	2023 HK\$'000 (Unaudited) 11,571 12,761 11,942 5,368 1,830

As at 31 December 2023, trade receivables of approximately HK\$41,642,000 (30 June 2023: approximately HK\$35,258,000) are not past due and regarded as having low default risk by the management of the Company based on regular repayment history in the expected credit loss assessment. As at 31 December 2023, no trade receivables (30 June 2023: HK\$NiI) were pledged to secure bank borrowings.

For the six months ended 31 December 2023

10. TRADE PAYABLES

The average credit period on purchases of goods ranges from 30 to 180 days. The Group has financial risk management policies to ensure that all payables are paid within the credit timeframe. The aging analysis of trade payables based on the invoice date, is as follows:

	31 December	30 June
	2023	2023
	HK\$'000	HK\$'000
	(Unaudited)	(Audited)
0-30 days	9,414	28,923
31-60 days	2,890	32,534
61-90 days	260	_
91-180 days	54,580	198
Over 180 days	12,330	2,290
Total	79,474	63,945

11. FINANCIAL RISK MANAGEMENT AND FINANCIAL INSTRUMENTS

The Directors consider that the carrying amounts of financial assets and financial liabilities recorded at amortised cost in the condensed consolidated financial statements approximate their respective fair value.

Financial risk factors

The Group's activities expose it to a variety of financial risks: market risk (including foreign currency risk and interest rate risk), credit risk and liquidity risk.

The condensed consolidated financial statements do not include all financial risk management information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual financial statements for the year ended 30 June 2023.

There have been no changes in the risk management policies since 30 June 2023.

For the six months ended 31 December 2023

12. RELATED PARTY TRANSACTIONS

(a) Related party transactions

In addition to those related party transactions disclosed elsewhere in the condensed consolidated financial statements, the Group had the following transactions with its related parties during the periods:

	Six months ended 31 December	
	2023	2022
	HK\$'000	HK\$'000
	(Unaudited)	(Unaudited)
Interest expenses on loans from the ultimate holding company	78	34
Interest expenses on loan from Mr. Lam	_	245
Salaries to the spouse of Mr. Lam	_	360
Salaries to Mr. Lam Ka Chun	120	240

As at 31 December 2023, loan facilities granted by the ultimate holding company to the Company amounted to approximately HK\$70,000,000 (30 June 2023: approximately HK\$70,000,000).

For the six months ended 31 December 2023

12. RELATED PARTY TRANSACTIONS (Continued)

(b) Related party balances

In addition to those related party balances disclosed elsewhere in the condensed consolidated financial statements, the Group had the following balances with its related parties as at the end of the reporting period:

As at 31 December 2023, the convertible bonds amounting to approximately HK\$51,751,000 (30 June 2023: approximately HK\$46,865,000) were held by Mr. Lam, and the convertible bonds amounting to approximately HK\$21,137,000 (30 June 2023: approximately HK\$22,864,000) were held by Chinese Success Limited, the immediate holding company of the Company.

(c) Key management personnel remuneration

The remuneration of the Directors and other members of key management personnel during the periods are as follows:

	Six months ended 31 December	
	2023	2022
	HK\$'000	HK\$'000
	(Unaudited)	(Unaudited)
Salaries and allowances	253	510
Retirement benefit scheme contributions	9	8
Total	262	518